Plaintiffs in over 90 lawsuits allege that widely prescribed GLP-1 drugs—used to treat diabetes and obesity—have caused a rare eye condition in patients. The legal cases suggest a potential link between these medications and serious vision-related side effects, raising concerns about their safety profile. Regulatory scrutiny may intensify as the claims highlight growing public health questions about long-term drug risks. Legal experts and medical professionals are closely watching the developments for possible broader implications.
More than 90 lawsuits against GLP-1 companies claim rare eye condition resulted from diabetes and weight loss drugs.
